Elon Musk is recognized as an innovator across various sectors, from electric cars to interstellar travel. However, one of his most contentious initiatives is Neuralink Corp., a brain implant technology designed to rectify neurological disorders and facilitate communication between brains. In total, accredited investors have invested a whopping $363 million into Musk’s Neuralink. But retail investors are another unlikely crowd that have recently begun investing substantially into the neurotech space. TruBrain is a startup currently live on StartEngine, meaning anyone can invest in TruBrain for a limited time. TruBrain is building FDA-cleared wearable technology to reduce stress and anxiety.
Click here to invest in TruBrain.
Following Musk’s establishment of the company, numerous startups have sprung up to offer competition. Notably, Synchron, a company supported by high-profile investors such as Bill Gates and Jeff Bezos, recently secured $75 million in venture funding to rival Neuralink.
Retail investors have surprisingly joined the ranks, pouring millions into this emerging field.
Due to recent changes in federal law, anyone can now invest in high-growth startups via platforms like StartEngine and Wefunder. These platforms host hundreds of startups, enabling everyone from retail investors to billionaires to back high-growth startups.
Venture-backed TruBrain is raising funds on the platform and has experienced significant growth. TruBrain has already amassed over $2.3 million from thousands of retail investors in previous raises for its FDA-approved wearable brain tech. The company recently relaunched another campaign, meaning anyone can invest.
Deep Knowledge Ventures reports that investments in neurotech companies have soared by over 600%, from $1.1 billion in 2014 to $7.1 billion in 2021. The neurotech market is projected to almost triple in size over the next decade to $38 billion. Despite its considerable size, the market is still largely unexplored with no dominant players, implying that startups are currently vying to secure their market position in anticipation of substantial future returns.
A majority of these companies’ technologies are centered around medical applications. For instance, TruBrain’s wearable tech is engineered to alleviate stress and anxiety. Synchron, on the other hand, aims to restore lost functionality with neuroprosthetics, enabling the reconstruction of neural pathways in patients suffering from severe paralysis.
In early 2022, rumors emerged that Apple Inc. had initiated development on a brain-computer interface (BCI) akin to Neuralink and Synchron.
While Neuralink’s technology is primarily aimed at medical applications, Musk has championed it as a tool for linking individuals’ brains together. Musk suggests that this could facilitate a form of telepathy among Neuralink users, allowing them to communicate with other Neuralink users solely via their thoughts. Musk has also showcased the capability to interact with electronic devices using Neuralink. This was demonstrated in a video Neuralink released in early 2021, showing a monkey playing Pong using the technology.
Click here to invest in TruBrain.
See more on startup investing from Benzinga.
- Collaborative Robots Startup Using Teams Of AI-Powered Drones To Make Flying Safer
- AI Startups Turn to Retail Investors To Fund the Growth of the $1.59 Trillion Artificial Intelligence Market
Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer's securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information.
TruBrain’s Reg A+ offering is made available through StartEngine Primary, LLC, member FINRA /SIPC.This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view TruBrain’s offering circular and risks associated with this offering.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
